CONNECTA Therapeutics is a Barcelona-based clinical-stage biotech developing CTH120, a neuroplasticity modulator now in Phase IIa trials for Fragile X syndrome.
This profile is maintained by the Sesamers data desk. Claim it to edit details, post jobs and answer interviews.
€3,100,000
Total raised
-
Valuation
-
Employees
-
Founded
Latest round
Series A - September 10, 2026
Series A - €3,100,000
September 10, 2026
Inveready, CDTI Innvierte, Prous Institute for Biomedical Research
✓ verified by our desk
Open roles
CONNECTA Therapeutics is not hiring through Sesamers right now.
Work here? Claim the profile and post roles.
Claim your profile